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DICER1, an endoribonuclease required for microRNA (miRNA) biogenesis, is essential for embryogenesis and the
development of many organs including ovaries. We have recently identified somatic hotspot mutations in RNase
IIIb domain of DICER1 in half of ovarian Sertoli-Leydig cell tumors, a rare class of sex-cord stromal cell tumors in
young women. These hotspot mutations lost IIIb cleavage activity of DICER1 in vitro and failed to produce 5p-
derived miRNAs in mouse Dicer1-null ES cells. However, the oncogenic potential of these hotspot DICER1
mutations has not been studied. Here, we further revealed that the global expression of 5p-derived miRNAs was
dramatically reduced in ovarian Sertoli-Leydig cell tumors carrying DICER1 hotspot mutations compared with
those without DICER1 hotspot mutation. The miRNA production defect was associated with the deregulation of
genes controlling cell proliferation and the cell fate. Using an immortalized human granulosa cell line, SVOG3e, we
determined that the D1709N-DICER1 hotspot mutation failed to produce 5p-derived miRNAs, deregulated the
expression of several genes that control gonadal differentiation and cell proliferation, and promoted cell growth.
Re-expression of let-7 significantly inhibited the growth of D1709N-DICER1 SVOG3e cells, accompanied by the
suppression of key regulators of cell cycle control and ovarian gonad differentiation. Taken together, our data
revealed that DICER1 hotspot mutations cause systemic loss of 5p-miRNAs that can both drive pseudodiffer-
entiation of testicular elements and cause oncogenic transformation in the ovary.
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Ovarian Sertoli-Leydig cell tumors (SLCTs) are a rare type of sex-cord
stromal tumors (SCSTs) in the ovary, accounting for less than 0.5%
of all ovarian tumors [1]. SLCTs, occurring in young women with the
median age of diagnosis around 28 years old, are often associated with
androgenic manifestations and pelvic mass [2,3]. Immunohistochem-
istry markers, such as EMA, Melan-A, and inhibin, are often useful in
distinguishing SLCTs from other malignancies, although proper
diagnosis of SLCTs can sometime remain challenging because of the
lack of unique genomic features [3]. The prognosis of SLCTs
correlates with the degree of histologic differentiation of the tumors
[3,4]. Although surgery is the primary treatment for SLCT patients,
intermediate and poorly differentiated SLCTs can recur and need
effective postoperative treatment [2,4].
SLCTs of the ovary contain Sertoli cells and Leydig cells, both of
which are somatic cells in male gonads. Thus, SLCTs of the ovary
represents a pseudo–male gonadal genesis in the ovary. Using a laser
capture microdissection method, Emerson et al. demonstrated that
both Sertoli cells and Leydig cells in ovarian SLCTs shared common
molecular features at several genomic loci, indicating that they are
possibly derived from the same primitive cells during neoplastic
transformation [5]. Significant ultrastructural and histologic similar-
ities have been observed between Sertoli cells of SLCTs and neoplastic
granulosa cells using electron microscopy and immunohistochemistry
[6,7], suggesting that Sertoli cells in SLCTs may derive from
primitive cells that normally differentiate into granulosa cells
(pregranulosa cells) in the ovarian gonad [8,9]. However, it remains
unclear how the differentiation of the primitive cells is rewired to
stimulate the production of Sertoli and Leydig cells in the ovary.
Studies of a few cases of SLCTs suggested that SRY-independent
induction of SOX9 expression might contribute to the pseudogona-
dal biogenesis [7,10]. However, the significance of these studies needs
to be determined in a large cohort of SLCTs.
Recently, we and others have discovered that more than 50%
ovarian SLCTs harbor somatic heterozygous mutations at one of the
five hotspot sites (E1705, D1709, E1788, D1810, or E1813) in the
metal-binding catalytic cleft of the DICER1 RNase IIIb endoribo-
nuclease domain [11,12]. DICER1 plays a crucial role in the
maturation of microRNAs (miRNAs), a group of noncoding small
RNA species that regulate gene expression posttranscriptionally [13].
Importantly, tumor cells with DICER1 hotspot mutations often have
loss of function defects in the other allele due to germline or other
somatic events [11], suggesting that the allele with the hotspot
mutation is the primary functional allele in miRNA biogenesis. Using
in vitro DICER1 cleavage assays and ex vivo isogenic cell lines
expressing DICER1 variants in dicer1-null mouse embryonic stem
cells, we and others concluded that the hotspot RNase IIIb domain
mutation of DICER1 leads to loss of RNase IIIb enzymatic activity
and subsequent loss of miRNAs generated from 5p strand of miRNA
precursors [11,14,15]. Similarly, biallelic mutations of DICER1 have
been identified in other tumors, such as a subset of Wilms tumors and
pleuropulmonary blastoma [16,17]. However, whether hotspot
mutations in the RNase IIIb domain of DICER1 alter miRNA and
gene expression in SLCTs and how these hotspot mutations promote
oncogenic transformation in specific tissue types are unknown.
In this study, we analyzed the global miRNA and gene expression
in SLCTs with and without DICER1 hotspot mutations. We
demonstrated that DICER1 hotspot mutations were associated with
the global reduction of 5p-derived miRNAs in ovarian SLCTs as wellas with the deregulation of genes governing cell proliferation and
differentiation in ovary. Using an immortalized human granulosa cell
line, SVOG3e, we demonstrated that a DICER1 hotspot mutation
promoted cell proliferation and regulated the expression of cell
proliferation and differentiation genes, partially through silencing the
expression of the let-7 miRNA family.
Material and Methods
Patient Samples and RNA Extraction
All the tumor samples were collected from the Ovarian Cancer
Research Program tissue bank in Vancouver, British Columbia,
Canada. Ethics approvals for collection and use of the patient samples
were obtained from the University of British Columbia and BC
Cancer Agency Research Ethics Board [11]. RNA was extracted using
the miRNeasy or the miRNeasy formalin-fixed, paraffin-embedded
(FFPE) kits (Qiagen) according to the manufacturer’s protocols.
Small RNA Sequencing
Total RNA was quantified with the Qubit RNA BR Assay Kit (Life
Technologies) and diluted to 200 ng/μl. Small RNA libraries were
prepared using the TruSeq Small RNA Sample Preparation Kit from
Illumina according to the manufacturer’s instructions. Briefly, total
RNA was ligated to 3’ and 5’ adapters and subsequently reverse
transcribed to produce a single-stranded cDNA. cDNA was
amplified, and index adapters were added by polymerase chain
reaction (PCR). PCR products were pooled for gel purification and
quantified. DNA was denatured and diluted to 10 to 12 pM before
loading to the MiSeq V2 reagent cartridge (50 cycles). The fastq files
generated from the MiSeq were analyzed using GenomeStudio data
analysis software provided with the MiSeq instrument with alignment
to the hg19 reference human genome. MiRBase 19 was used for
miRNA annotation. Normalized miRNA reads (reads per million
reads) were determined by the formula: normalized miRNA reads =
(raw reads of individual miRNAs)/(the total number of aligned small
RNA reads in the corresponding library)*(one million).
miRNA Real-Time PCR
Individual miRNAs were quantified using Exiqon’s PCR system
following the manufacturer’s instructions. Briefly, 10 ng of total RNA
was first converted to cDNA, which was then mixed with the PCR
master mix and the PCR primer mix. PCRs were incubated in a
384-well plate at 95°C for 10 minutes, followed by 40 cycles of 95°C
for 10 seconds and 60°C for 1 minute. miRNAs were assayed in
triplicate, and data were normalized to the endogenous small nuclear
RNA RNU1A1.
Illumina Whole-Genome DASL Microarray Analysis
RNA quality was determined by Taqman gene expression assay of
RPL13A expression. SLCTs with and without DICER1 mutations
(four for each subtype) were included for the analysis. A total of 200
ng of RNA was analyzed using the Illumina Whole-Genome DASL
(cDNA-mediated annealing, selection, extension, and ligation) assay
with the Human HT-12 v4 BeadChip following the manufacturer’s
instruction. Fluorescence intensities of the extracted images were read
on a BeadArray Reader, which were analyzed by BeadStudio software
followed by visualization in GeneSpring GX (v12, Agilent). Ingenuity
pathway analysis was performed with differentially expressed genes
(fold change N 2, P b .05). Raw data are available in the NCBI GEO
database, Accession No. GSE71160.
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Multigene assay was applied to tumor or cell line samples using the
Nanostring nCounter GX CodeSet Kit (NanoString Technologies).
The total RNA (500 ng for FFPE samples, 100 ng for cell line
samples) was hybridized with the available 45-gene code set for 18
hours at 65°C and processed according to manufacturer’s instructions
[18]. ACTB, GAPDH, and EDEM3 served as internal controls.
Cell Culture and miRNA Mimic Transfection
SVOG3e cells, which derived from SV40 T-antigen–immortalized
primary human granulosa cell line [19] by further introduction of
hTERT, were maintained in Dulbecco’s modified Eagle’s medium–
F12 medium (Hyclone) supplemented with 10% fetal bovine serum
at 37°C and 5% CO2. The synthetic hsa-let-7a mimic (Dharmacon)
was transfected into cells with Lipofectamine RNAiMax reagent (Life
Sciences) at 10 nM.
Plasmid Construction and Virus Production
DICER1 D1709N mutant was generated from pDONR_wildtype
(WT) [5] by site-directed mutagenesis (QuikChange II XL
Site-Directed Mutagenesis Kit, Agilent). WT or D1709N DICER1
sequences in pDONR221 vectors were shuttled into pLD-hygro-
EnVM vectors [20] (Addgene # 24590) with Gateway LR-clonase
reaction (Invitrogen) following the manufacturer’s protocol. Sanger
sequencing verified the DICER1 mutations in the vectors.
GFP-expressing vectors were used as the vector controls. A CRISPR
gRNA (CCCCTATCGAGAAATTATGA) targeting the exon5/
intron junction of human DICER1 was cloned into LentiCRISPR
vector [21] (Addgene #49535). To produce lentivirus expressing
DICER1 or DICER1 gRNA/cas9, pLD-hygro-EnVM-DICER1
(WT or D1709N) or LentiCRISPR-DICER1 was cotransfected
with packaging plasmids psPAX2 and pMD2.G into HEK293T cells
using Mirus LT-1 reagent. The pMSCVpuro-let-7 sponge vector [22]
(Addgene #29766) was cotransfected with Ampho-V packaging
plasmid into HEK293T cells using Mirus LT-1 reagent. Supernatants
were collected at 48 or 72 hours for retrovirus or lentivirus
preparation, respectively.
Cell Growth Assay
Cells were plated in 96-well plates at 2000 cells per well with 5
replicates. Cell growth was monitored for 7 days using the IncuCyte
ZOOM Live Cell Imaging System (Essen BioScience). Percentage of
cell confluence, the fractional area occupied by cells, was calculated to
determine the cell growth rate.
Statistical Analysis
All statistical analyses were performed using the independent t test
in EXCEL or the one-way analysis of variance for multiple
comparisons in PRISM 6. Results were considered statistically
significant when P values were b .05.
Results
Deregulation of miRNA Biogenesis in Ovarian SLCTs
To reveal the impact of DICER1 RNase IIIb domain mutation on
miRNA production in tumors, we analyzed the miRNA expression
profiles in ovarian SLCTs using the Illumina Small RNA Sequencing
technology. Because the majority of our SLCTs were FFPE samples,
we first compared the miRNA expression profiles in the frozen and
FFPE tumor samples from two patients. MiSeq analysis of miRNAexpression in matched frozen and FFPE samples showed good
correlation between FFPE tumor samples and their frozen counter-
parts (Pearson correlation R2 = 0.90 and 0.83, respectively;
Supplemental Figure S1), indicating that the Illumina Small RNA
Sequencing technology could reliably detect miRNA expression in
FFPE samples.
Next, we sequenced small RNAs in five SLCTs with DICER1
RNase IIIb hotspot mutations and six SLCTs without DICER1
hotspot mutations, all of which were FFPE samples. Consistent with
our data in isogenic mouse embryonic stem cells expressing DICER1
variants [14], the average percentage of 5p-derived miRNAs in the
whole miRNA population decreased dramatically from 63.1% in
tumors without DICER1 hotspot mutation to 25.1% in tumors with
DICER1 hotspot mutations (Figure 1A, P b .001; and Supplemental
Table S1). Among the 135 miRNAs whose average reads were at least
10 per million reads across all the samples, the expression of 90.5%
(57/63) 5p-derived miRNAs and 25% (18/72) 3p-derived miRNAs
decreased dramatically in SLCTs with DICER1 hotspot mutations
compared with those without hotspot mutations (Figure 1B and
Supplemental Table S2). Interestingly, the expression of 26% (19/72)
3p-miRNAs was significantly increased in SLCTs with DICER1
hotspot mutation versus those without DICER1 hotspot mutation
(Figure 1B and Supplemental Table S2). The expression ratio of the
5p- and 3p-derived miRNAs (5p/3p ratio) of 20 miRNA pairs whose
precursors produce miRNAs from both 5p and 3p strands in SLCTs
was significant reduced in SLCTs with DICER1 mutation versus
those without DICER1 hotspot mutations (Figure 1C, P b .01),
further supporting that there is a defect in producing mature miRNAs
from the 5p-strand of pre-miRNAs.
Next, we validated the expression of selected 5p- and 3p-derived
miRNAs by real-time PCR in 41 SLCT FFPE samples (21 SLCTs
with DICER1 hotspot mutations and 20 without DICER1 hotspot
mutations, Supplemental Table S3). The expressions of miR-26a-5p,
let-7f-5p, and miR-125b-5p were all dramatically reduced in tumors
with DICER1 hotspot mutations compared with those in tumors
without DICER1 hotspot mutations (Figure 2A, P b .001), whereas
no significant difference was observed for the expression of
miR-143-3p, miR-92a-3p, and miR-22-3p between SLCTs with or
without DICER1 hotspot mutations (Figure 2B). The decrease of
5p-derived miRNAs did not depend on the specific site of RNase IIIb
mutation present (Figure 2C). Therefore, both the miRNA
sequencing and real-time PCR data support a miRNA biogenesis
defect in SLCTs with DICER1 RNase IIIb hotspot mutations.
Association Between DICER1 Hotspot Mutations and Altered
Expression of Cell Growth and Development Genes
MiRNAs fine-tune gene expression largely through causing mRNA
degradation [23]. To understand the biological impact of DICER1
hotspot mutation–mediated miRNA biogenesis defects in SLCTs, we
compared the mRNA expression profiles of four SLCTs with hotspot
DICER1 mutation and four SLCTs without hotspot DICER1
mutation using the Illumina DASL whole transcriptome analysis.
Clustering analysis revealed that the gene expression profiles of four
SLCTs with DICER1 hotspot mutations tightly clustered together,
deviating away from those of four SLCTs without DICER1 hotspot
mutations (Figure 3A). Ingenuity pathway analysis of 1396
differentially expressed genes (fold change N 2, P b .05, Supplemental
Table S4) revealed an enrichment of genes regulating cell survival,
proliferation, and development (Figure 3B), suggesting that SLCTs
Figure 1.Global loss of 5p-derivedmiRNAs in SLCTs with DICER1 hotspot mutations. (A) Percentage of total 5p-derivedmiRNA reads was
determined by calculating the ratio of the total reads of 5p-derived miRNAs to that of all miRNAs. (B) The number of significantly altered
5p- and 3p-derived miRNAs between SLCTs with and without DICER1 hotspot mutations. (C) The expression ratio of 5p- and 3p-miRNAs
derived from the same precursor was calculated in each SLCT. ***P b .001.
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those without DICER1 hotspot mutations. Further analysis of 699
upregulated genes identified an enrichment of genes (115 genes) that
are either validated or predicted targets of let-7 family miRNAs
(Supplemental Table S5), a collection of miRNAs that constitute the
most abundantly expressed miRNAs in both normal human
granulosa cells [24] and SLCTs without DICER1 hotspot mutations
(Supplemental Figure S2), indicating that loss of let-7 miRNAs may
have important roles in SLCT development.
Next, the expression of a subset of genes (n = 34, Supplemental
Table S6), including the top 20 upregulated, top 8 downregulated
genes, and 7 selected predicted targets of let-7 from DASL whole
transcriptome analysis, was verified using the Nanostring nCounter
system in 41 FFPE SLCT tumor samples (Supplemental Table S3).
About 82% (27/34) of the selected genes exhibited significantly
differential expression between SLCTs with and without DICER1
hotspot mutations (Supplemental Table S6), indicating a high
correspondence with the DASL whole transcriptome analysis. In
particular, all the seven selected targets of let-7 were expressed at
significantly higher levels in SLCTs with hotspot DICER1 mutation
compared with those without DICER1 hotspot mutations
(Figure 3C), in agreement with the substantially lower amount of
let-7 in those tumors (Figure 2A). Therefore, the differential geneexpression between SLCTs with and without DICER1 hotspot
mutations may occur as a result of defective miRNA biogenesis.
Association BetweenDICER1HotspotMutations andDeregulation
of Gonadal Genesis Genes
Only a few genes crucial for gonadal genesis, such as CYP19A1
(aromatase), had differential expression between SLCTs with and
without DICER1 hotspot mutations in the microarray analysis
(Supplemental Table S3). However, because SLCTs of the ovary
represents a pseudo–male gonadal genesis in the ovary, deregulation
of gonadal genes may occur despite the status of DICER1 mutations
in SLCTs. Thus, to ascertain the effect of DICER1 hotspot mutations
on gonadal genes, we reexamined the expression of selected gonadal
genes using the Nanostring nCounter system and compared them
with that of juvenile and adult granulosa cell tumors (jGCTs and
aGCTs, respectively), none of which had DICER1 hotspot mutations
(data not shown). We validated that the expression of CYP19A1,
encoding aromatase which controls estrogen synthesis from testos-
terone and differentiation of somatic cell lineages in ovarian gonad
[25], was remarkably lower in SLCTs with DICER1 hotspot
mutations than that in SLCTs without DICER1 hotspot mutation
(−7.8-fold, P b .001; Figure 4, A and B). In comparison to jGCTs
and aGCTs, the expression of CYP19A1 was significantly lower in either
Figure 2. Reduced expression of 5p-derived miRNAs (let-7, miR-26a, and miR-125b) in SLCTs with DICER1 hotspot mutations. Real-time
reverse transcriptase PCR was used to quantitate the expression of selected miRNAs in SLCTs and jGCTs. The expression of selected
5p-derived (A), but not 3p-derived (B), miRNAs was significantly reduced in SLCTs with DICER1 hotspot mutations. The decrease of
selected 5p-derived miRNAs did not depend on the specific site of RNase IIIb mutation present (C). ***P b .001.
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patients with SLCTs are often associated with elevated testosterone levels
[2]. Consistently, the mRNA levels of FSHR and PGR, two
estrogen-responsive genes crucial for ovulation, were significantly lower
in SLCTs with DICER1 hotspot mutations compared with their
counterparts (P b .05; Figure 4A), although it remained possible that their
expression might be suppressed by some upregulated miRNAs in SLCTs
with DICER1 hotspot mutation (Supplemental Table S7). Furthermore,
the expression of FST, the gene encoding follistatin that binds to activin
and functions downstream of Wnt4 to control ovarian development [9],
was significantly lower in SLCTs compared with granulosa cell tumors
(GCTs) (P b .01; Figure 4C). The expression of both FGF9 and FGFR2,
two genes crucial for Sertoli cell differentiation [9], was also significantly
higher in SLCTs than that in GCTs (Figure 4,D and E). Therefore, ourtranscriptome analysis suggests that DICER1 hotspot mutations may
have important contributions to the pseudo–male gonadal development
in the ovary of SLCT patients.
Regulation of Cell Proliferation and Differentiation Genes by
DICER1 Hotspot Mutations in Primary Granulosa Cells
To understand how the hotspot mutations of DICER1 promote
tumorigenesis in the ovary, we first engineered an immortalized
human primary granulosa cell line, SVOG3e, to express either WT or
D1709N DICER1. This cell line model was chosen because no
ovarian SLCT cell line has been established and the Sertoli and Leydig
cells in ovarian SLCTs are believed to originate from primordial cells
that normally differentiate into granulosa cells [6–9]. Because
DICER1 is an essential gene, we stably overexpressed either WT or
Figure 3. SLCTs with hotspot DICER1 mutations have similar global gene expression landscapes. (A) Clustering of SLCTs based on their
global gene expression landscape. (B) Top molecular and cellular functions affected by DICER1 hotspot mutations. (C) Increased
expression of let-7 targets in SLCTs with DICER1 hotspot mutations. **P b .01, ***P b .001.
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endogenous DICER1 gene using a CRISPR gRNA (LentiCRISPR-
DICER1) that targets the exon5-intron5 boundary (Supplemental
Figure S3). This strategy led to the generation of isogenic SVOG3e
cell lines that predominantly expressed either V5-tagged WT or
D1709N DICER1 (named SVOG3e-WT or SVOG3e-D1709N,
respectively) (Supplemental Figure S4 and Figure 5A). The expression
of several 5p-derived miRNAs, such as let-7f-5p, miR-26a-5p, and
miR-125b-5p, was significantly reduced in SVOG3e-D1709N
DICER1 cells compared with SVOG3e-WT DICER1 cells, whereas
the expression of several 3p-derived miRNAs was largely unaffected
(Figure 5B). Interestingly, the expression of miR-181a (5p)
and miR-181a-2-3p was significantly reduced and increased
(Supplemental Figure S5), respectively, supporting the observation
that the expression of a portion of 3p-derived miRNAs was increased
in SLCTs with DICER1 hotspot mutations (Supplemental Table
S7). Thus, our isogenic DICER1 variant SVOG3e model confirmed
that hotspot mutations in the RNase IIIb domain of DICER1 are
defective in the maturation of miRNAs originated from 5p strands of
pre-miRNAs.
Next, the expression of the 34 top deregulated genes or let-7 targets
and 8 selected gonadal genes (Figure 4A) was determined in isogenic
DICER1 SVOG3e cell lines using the Nanostring platform. Among
the 42 genes, only 16 genes were expressed in SVOG3e cells, with
half of them displaying differential expression between the isogenic
pairs (Figure 5C). In agreement with the differential expression
between SLCTs with or without DICER1 hotspot mutations,
SVOG3e-D1709N cells had significantly lower expression of FST
and MGST1 genes than SVOG3e-WT cells but expressed higher
amount of FGF9, SOX9, CCNF, CDC25A, PLAGL1, and ARID3A
than their counterpart (Figure 5C). The effect of DICER1 D1709N
on the increased expression of CDC25A and SOX9 was further
confirmed by Western blotting (Figure 5A). Furthermore, theSVOG3e-D1709N cells proliferated significantly faster than the
SVOG3e-WT cells (Figure 5D), in agreement with the induction of
cell growth–promoting genes ARID3A, CDC25A, and PLAGL1
[26–28] (Figure 5C). Therefore, our data support a causal role for
DICER1 hotspot mutations in mediating the pseudo–male gonadal
development and oncogenesis in the ovary.
The Role of Let-7 in DICER1 Hotspot Mutation–Mediated
Differentiation and Oncogenesis
The highly conserved let-7 family miRNAs have important roles in
differentiation and proliferation [29,30]. Particularly, substantially
higher levels of let-7 were found in sheep ovary versus sheep testis
[31], suggesting a potential role of let-7 miRNAs in ovary
development. Furthermore, the let-7 family miRNAs constitute the
most abundant miRNAs in normal human granulosa cells [24] and
SLCTs without DICER1 hotspot mutations (Supplemental Figure
S2). Thus, we investigated whether loss of let-7 miRNAs contributed
to DICER1 hotspot mutation–mediated phenotypic changes.
Expression of a let-7 synthetic miRNA mimic robustly reduced the
expression of CCNF, CDC25A, PLAGL1, and ARID3A, four
published or predicted targets of let-7; upregulated the expression of
FST (Figure 6A); and suppressed the proliferation of SVO-
G3e-D1709N cells (Figure 6B), suggesting that deregulation of
let-7 miRNAs may be a crucial event in DICER1 hotspot mutation–
mediated oncogenesis in the ovary. Furthermore, functional
inhibition of let-7 miRNAs with a miRNA sponge [22] upregulated
the expression of two known let-7 targets, CDC25A and DICER1
[32,33], by Western blotting in the parental SVOG3e cells
(Figure 6C), suggesting an efficient suppression of the let-7 function
by the let-7 sponge. Accordingly, the SVOG3e-let-7 sponge–
expressing cells proliferated faster than the control cells (Figure 6D),
supporting a physiological role for let-7 miRNAs in controlling the
proliferation of ovarian granulosa cells.
Figure 4. Expression of gonadal genesis genes is changed in SLCTs and GCTs with and without hotspot DICER1 mutations. Nanostring
nCounter systemwas used to determine the expression of a selected panel of gonad genesis genes in SLCTs or GCT FFPE samples (A–E).
The transcript counts of each gene in the 500 ng of RNA samples were normalized to those of a panel of control genes in Material and
Methods. *P b .05, **P b .01, ***P b .001.
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DICER1 controls the biogenesis of miRNAs and is essential for
embryogenesis and development of many organs. Although early
mouse models suggested that DICER1 functioned as a haploinsuffi-
cient tumor suppressor, recent genomic studies by others and our
own laboratory suggest a distinct role of DICER1 in the oncogenesis
of specific tumor types. Germline mutations of DICER1 have been
well documented in a wide range of tumors in a cancer predisposition
syndrome, the so-called DICER1 syndrome [34–37]. Since our first
report of somatic hotspot mutations in the RNase IIIb domain of
DICER1 in nonepithelial ovarian tumors (particularly SLCTs of the
ovary) [11], several groups have described that missense mutations of
the DICER1 RNase IIIb domain occur frequently in DICER1
syndrome patients, indicating a “two-hit” tumor-suppressive model
of DICER1. However, unlike classic “two-hit” models, our previous
[11,14] and present studies determined that the second hit of
DICER1 mutations generates a partially functional allele that elicits amiRNA biogenesis bias, leading to systemic loss of 5p-derived
miRNAs in SLCTs and the maintenance or increase of 3p-derived
miRNAs. Importantly, DICER1 hotspot mutations lead to aberrant
cell proliferation and deregulation of genes regulating cell growth and
gonad genesis. Therefore, we have provided evidence that hotspot
mutations in the RNase IIIb domain of DICER1 produce an
oncogenic allele.
Ovarian sex-cord stromal cell tumors include a collection of
distinct subtypes with variable clinical presentations and prognosis,
such as GCTs and SLCTs. Proper diagnosis of SCSTs is often very
challenging because of the lack of specific markers; however, this is
improving because of our recent findings of the overwhelming
presence of the pathogenomic FOXL2 C134W mutation in N95%
GCTs [38,39] and the occurrence of DICER1 hotspot mutations in
about 50% of SLCTs [11]. In the current study, we demonstrate that
although there is no correlation between the histologic grades and
DICER1 mutational status of SLCTs, SLCTs with DICER1 hotspot
Figure 5. A DICER1 hotspot mutation affects miRNA and gene expression and cell proliferation in primary granulosa cells. Isogenic
SVOG3e cell lines expressing ectopic V5-tagged DICER1 (WT versus D1709N) with simultaneous ablation of the endogenous DICER1
allele by CRISPR/Cas9 technology were established and subjected to protein expression analysis by Western blotting (A), miRNA
expression analysis by quantitative real-time PCR (B), gene expression analysis by NanoString nCounter system (C), and cell proliferation
analysis by Incucyte Live Cell Imaging monitor (D).
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foci (8/21), a structure frequently seen in moderately and poorly
differentiated SLCTs [40], in comparison to SLCTs without
DICER1 hotspot mutations (2/20) (Supplemental Table S3).
Furthermore, SLCTs with DICER1 hotspot mutations displayed
distinct gene expression landscapes. Thus, SLCTs with and without
DICER1 hotspot mutations may possibly represent different diseases
with different patient outcomes. Notably, SLCTs with DICER1
hotspot mutations have significantly lower amount of CYP19A1, the
enzyme catalyzing the conversion of testosterone into estrogen [25],
suggesting that the function of estrogen is more severely attenuated in
this group of tumors. Given that SLCTs can be categorized into three
groups based on endocrine functions (androgen excess, estrogen
excess, and no endocrine function) [2], DICER1 hotspot mutations
may be more prevalent in patients with androgenic symptoms. Thus,
it will be interesting to determine whether the testosterone level in
SLCT patients correlates with mutational status in the RNase IIIb
domain of DICER1. Furthermore, SLCTs with DICER1 hotspot
mutations resembled each other at the transcriptional level regardless
of the specific site of where mutation occurred, whereas SLCTs
without DICER1 hotspot mutations were more heterogeneous(Figure 3A). We predict that continued efforts to identify the leading
genomic alternations in SLCTs without DICER1 hotspot mutations
and other SCSTs will eventually lead to the reclassification of SCSTs
based on genomic features and improve diagnosis accuracy.
The molecular mechanism underlying the unusual differentiation
of Sertoli and Leydig cells in the SLCTs of the ovary is largely
unknown. In this study, we demonstrated that DICER1 hotspot
mutation could alter the expression of key genes controlling the fate
determination of ovarian pregranulosa cells. These include the
downregulation of several key ovarian development genes, such as
FST and CYP19A1 [9,25], and the upregulation of two key Sertoli
cell differentiation genes, FGF9 and FGFR2, that are known to
stimulate Sertoli cell differentiation by sustaining the expression of
SOX9 [9,41]. The imbalance of gonadal gene expression may
therefore shift the differentiation of the primordial gonadal cells
towards a pseudotesticular cell differentiation in the ovary.
Noteworthily, although FGF9 and FGFR2 are known to stimulate
Sertoli cell differentiation by sustaining the expression of SOX9
[9,41] and ablation of CYP19A1 promoted differentiation of
Sertoli-like cells with SOX9 expression in mouse ovary [42], we
found that the SOX9 gene expression remained at low levels at both
Figure 6. Loss of let-7 promotes cell proliferation of primary granulosa cells harboring a DICER1 hotspot mutation. (A, B) SVOG3e cells
expressing D1709N were transfected with either synthetic negative control mimic (neg mimic) or let-7a mimic. Forty-eight hours later,
cells were harvested for gene expression analysis (A) or replated for measuring cell proliferation using Incucyte Live Cell Imaging monitor
(B). (C, D) SVOG3e cells stably expressing control or let-7 sponge were collected for Western blotting analysis of let-7 target genes (C) or
reseeded for determining cell proliferation with Incucyte Live Cell Imaging system (D).
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shown) in the majority of SLCTs. Interestingly, the expression of
SOX9 can be significantly upregulated by the D1709N DICER1
hotspot mutation in SVOG3e cells. These data favor a model in
which transient activation of SOX9 may be sufficient to initiate
Sertoli-like cell differentiation in ovarian pregranulosa cells and
sustained high level of SOX9 may be harmful for SLCT development
in some cases. Because both SLCTs with and without DICER1
mutation reflect a pseudo–male gonadgenesis in the ovary (i.e.,
reduced CYP19A1 expression), we speculate that SLCTs without
DICER1 mutation may arise from mutations in genes that govern the
developmental fate decision of primordial granulosa cells.
Global loss of 5p-drived miRNAs is believed to be the primary
driving force for DICER1 hotspot mutation–mediated tumorigenesis
in SLCTs and other DICER1 syndrome–associated tumors, which are
mostly primitive tumors. In particular, the let-7 family miRNAs, the
most abundant miRNA in normal human granulosa cells [24] and
SLCTs without DICER1 hotspotmutations (Supplemental Figure S2),
are important regulators of cell proliferation and differentiation [29,43].
In agreement with the tumor-suppressive role of let-7, we demonstrated
that inhibition of let-7 promoted granulosa cell proliferation and
restored expression of let-7 retarded the growth of SVOG3e-D1709Ncells. Importantly, we also report that the expression of FST was
increased by let-7 mimic expression (Figure 6A), suggesting that, in
addition to the role in embryonic stem cell differentiation, let-7 may
play specific roles in regulating ovarian pregranulosa cell differentiation.
However, some issues associated with the immortalized granulosa cell
line SVOG3e, such as nondetectable transcript and protein levels of
CYP19A1 and inability to express CYP19A1 upon cAMP stimulation
(data not shown) in SVOG3e cells, prevented us from testing the
relationship between any steroidogenic change or other differentiation
phenotypes andDICER1mutation status or let-7 function. Thus, some
better granulosa cell line models [44] or a transgenic animal model that
tightly expresses DICER1 hotspot mutation in ovarian granulosa cells
will help understand the oncogenic role of DICER1 hotspot mutations.
Interestingly, the expression of a subset of 3p-derived miRNAs was
significantly upregulated in SLCTs with DICER1 hotspot mutations
versus those without DICER1 hotspot mutations (Supplemental
Table S7). Some of them, such as miR-125b-1-3p, were shown to be
upregulated in the serum of a pleuropulmonary blastoma patient with
biallelic DICER1 mutations [45]. Although the mechanisms warrant
further study, the interruption of the negative feedback loop between
DICER1 and let-7 (and other 5p-derived miRNAs, such as miR-130a
[46]) may have stimulated the expression of the mutant DICER1
Neoplasia Vol. 17, No. 8, 2015 DICER1 RNase IIIb Domain Mutations in Cell Tumors Wang et al. 659allele and may thus promote the production of some 3p-miRNAs.
Alternatively, 3p-miRNAs normally degraded may be stabilized in the
absence of their more stable cognate 5p-miRNA. These 3p-derived
miRNAs are predicted to target some mRNAs that were differentially
expressed in hotspot and nonhotspot SLCTs (Supplemental Table S7),
suggesting that the selective upregulation of certain 3p-miRNAs in
SLCTsmay also contribute to the tumorigenesis of SLCTs in the ovary.
Taken together, our present study revealed that the selective
accumulation of hotspot mutations in the DICER1 RNase IIIb
domain in SLCTs causes defective miRNA biogenesis and gene
expression changes in key gonad development genes, and potentiate
proliferation, which may ultimately rewire differentiation and drive
oncogenesis in ovarian gonads.
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